Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Leukemia (14)
Blood Cancer Journal (8)
Bone Marrow Transplantation (2)
Nature (1)
Nature Medicine (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (13)
Correspondence (10)
Amendments and Corrections (2)
Reviews (1)

Subject Check one or more subjects to show results from those subjects only.

Biochemistry
Biological techniques
Cancer
Cell biology
Diseases
Health care
Medical research
Risk factors
Signs and symptoms

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–26 of 26 results

Advanced filters: Author: Francesca Palandri Clear advanced filters

Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea

Francesca Palandri
Massimo Breccia
Valerio De Stefano
ResearchOpen Access28 May 2025
Leukemia

P: 1-9
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

In a randomized phase 3 trial, the combination of the BET inhibitor pelabresib with the JAK inhibitor ruxolitinib resulted in a significantly higher spleen volume reduction from baseline versus placebo with ruxolitinib in patients with JAK inhibitor-naive myelofibrosis.

Raajit K. Rampal
Sebastian Grosicki
John Mascarenhas
ResearchOpen Access10 Mar 2025
Nature Medicine

Volume: 31, P: 1531-1538
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms

Inhibition of YBX1, a downstream target of the Janus kinase JAK2, sensitizes myeloproliferative neoplasm cells to JAK and could provide a means to eradicate such cells in human haematopoietic cancers.

Ashok Kumar Jayavelu
Tina M. Schnöder
Florian H. Heidel
Research25 Nov 2020
Nature

Volume: 588, P: 157-163
Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

Carl C. Crodel
Kathleen Jentsch-Ullrich
Florian H. Heidel
Amendments and Corrections10 Jul 2020
Leukemia

Volume: 34, P: 3106
Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study

Carl C. Crodel
Kathleen Jentsch-Ullrich
Florian H. Heidel
Research30 May 2020
Leukemia

Volume: 34, P: 1949-1953
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

Francisco Cervantes
David M. Ross
Haifa Kathrin Al-Ali
Amendments and Corrections02 Sept 2021
Leukemia

Volume: 35, P: 3626
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients

Tiziano Barbui
Valerio De Stefano
John Mascarenhas
Research19 May 2021
Leukemia

Volume: 35, P: 2989-2993
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Tiziano Barbui
Alessandro Maria Vannucchi
Alessandro Rambaldi
Research07 Jan 2021
Leukemia

Volume: 35, P: 485-493
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

Tiziano Barbui
Valerio De Stefano
Alessandro Maria Vannucchi
ResearchOpen Access04 Feb 2021
Blood Cancer Journal

Volume: 11, P: 1-11
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Tiziano Barbui
Arianna Ghirardi
Guido Finazzi
Research29 May 2019
Leukemia

Volume: 33, P: 1996-2005
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms

Valerio De Stefano
Alessandra Carobbio
Tiziano Barbui
ResearchOpen Access28 Feb 2018
Blood Cancer Journal

Volume: 8, P: 1-12
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Francesca Palandri
Giuseppe Alberto Palumbo
Massimiliano Bonifacio
CorrespondenceOpen Access07 Jan 2021
Blood Cancer Journal

Volume: 11, P: 1-4
How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey

Francesca Palandri
Alfonso Piciocchi
Alessandro M. Vannucchi
CorrespondenceOpen Access03 Jul 2020
Leukemia

Volume: 34, P: 2805-2808
Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin

Tiziano Barbui
Arianna Ghirardi
Alessandro Rambaldi
Correspondence07 Nov 2019
Leukemia

Volume: 34, P: 1208-1209
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients

Barbara Mora
Paola Guglielmelli
Francesco Passamonti
Research30 Aug 2022
Leukemia

Volume: 36, P: 2453-2460
Breakthrough infections in MPN-COVID vaccinated patients

Tiziano Barbui
Alessandra Carobbio
Alessandro Maria Vannucchi
CorrespondenceOpen Access15 Nov 2022
Blood Cancer Journal

Volume: 12, P: 1-6
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

Francisco Cervantes
David M. Ross
Haifa Kathrin Al-Ali
ResearchOpen Access20 May 2021
Leukemia

Volume: 35, P: 3455-3465
Second versus first wave of COVID-19 in patients with MPN

Tiziano Barbui
Alessandra Iurlo
Alessandro Maria Vannucchi
Correspondence21 Jan 2022
Leukemia

Volume: 36, P: 897-900
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B₂ assay as an evaluation tool of different aspirin dosing regimens in the clinical setting

Valerio De Stefano
Bianca Rocca
Carlo Patrono
ResearchOpen Access01 Jun 2018
Blood Cancer Journal

Volume: 8, P: 1-9
Long-term follow-up of recovered MPN patients with COVID-19

Tiziano Barbui
Alessandra Iurlo
Alessandro Rambaldi
CorrespondenceOpen Access16 Jun 2021
Blood Cancer Journal

Volume: 11, P: 1-4
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis

F Palandri
R Latagliata
N Vianelli
Research24 Mar 2015
Leukemia

Volume: 29, P: 1344-1349
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

Francesca Palandri
Elena M. Elli
Massimo Breccia
CorrespondenceOpen Access03 May 2023
Blood Cancer Journal

Volume: 13, P: 1-5
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis

F Palandri
M Amabile
M Baccarani
Correspondence08 Jan 2007
Bone Marrow Transplantation

Volume: 39, P: 189-191
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey

Massimo Breccia
Alfonso Piciocchi
Alessandro M. Vannucchi
Correspondence25 Aug 2020
Leukemia

Volume: 34, P: 2813-2814
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project

Daniela Barraco
Barbara Mora
Francesco Passamonti
CorrespondenceOpen Access21 Sept 2018
Blood Cancer Journal

Volume: 8, P: 1-4
The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review

Mario Tiribelli
Francesca Palandri
Massimiliano Bonifacio
ReviewsOpen Access18 Sept 2019
Bone Marrow Transplantation

Volume: 55, P: 708-716